0001628280-23-038926 | 10-Q | XBRL Viewer

Print Document View Excel Document

Commitments and Contingencies (Details) $ in Millions	Oct. 13, 2023 USD ($)	Sep. 30, 2023 patent	Sep. 18, 2023 USD ($) payment	Sep. 15, 2022 patent	Dec. 22, 2020 patent	Dec. 14, 2020 patent
Loss Contingencies [Line Items]
Number of quarterly payments \| payment			13
Quarterly awarded amount \| $			$ 0.1
Amount awarded from other party \| $			$ 1.4
Subsequent event
Loss Contingencies [Line Items]
Proceeds from settlements \| $	$ 0.1
Edge Systems LLC v. Cartessa Aesthetics, LLC
Loss Contingencies [Line Items]
Number of patents infringed upon \| patent		3		3		5
Revised number of patents infringed upon \| patent						4
Edge Systems LLC v. Ageless Serums LLC
Loss Contingencies [Line Items]
Number of patents infringed upon \| patent					6

Revision for Immaterial Misstatements

9 Months Ended

Sep. 30, 2023

Quarterly Financial Information Disclosure [Abstract]

Revision for Immaterial Misstatements

As disclosed in Note 1 – Description of Business, subsequent to the issuance of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, during the six months ended June 30, 2023, the Company identified misstatements related to the elimination of intercompany balances and right of return assets. Although the Company concluded that these misstatements were not material, either individually or in the aggregate, the Company elected to revise its previously issued consolidated financial statements to correct for these misstatements. The revision to the accompanying unaudited condensed consolidated balance sheets, condensed consolidated statements of comprehensive income (loss), and condensed consolidated statements of cash flows and related disclosures in Note 3 – Balance Sheet Components and Note 13 – Net (Loss) Income to Common Stockholders are detailed in the tables below.

As of December 31, 2021 and June 30, 2022, accumulated deficit was understated by $4.3 million and $6.9 million, and as such, previously reported stockholders’ equity of $302.3 million and $352.3 million was revised to $298.0 million and $345.4 million, respectively. For the fiscal year ended December 31, 2022, net income was overstated $0.2 million. As of March 31, 2023, accumulated deficit was overstated $4.7 million, and as such, previously reported stockholders’ equity of $147.7 million was revised to $152.4 million. There were no other changes to the consolidated statements of stockholders’ equity that have not otherwise been reflected in the condensed consolidated balance sheets and condensed consolidated statements of comprehensive income (loss) as detailed in the tables below.


	As of December 31, 2022
Condensed Consolidated Balance Sheet (in thousands)	As Previously Reported		Adjustment		As Revised
Inventories	$	116,430	$	(6,774)	$	109,656
Prepaid expenses and other current assets	$	26,698	$	950	$	27,648
Total current assets	$	789,099	$	(5,824)	$	783,275
TOTAL ASSETS	$	1,008,907	$	(5,824)	$	1,003,083
Accounts payable	$	30,335	$	(1,868)	$	28,467
Income tax payable	$	962	$	467	$	1,429
Total current liabilities	$	73,115	$	(1,401)	$	71,714
TOTAL LIABILITIES	$	837,431	$	(1,401)	$	836,030
Accumulated deficit	$	(374,328)	$	(4,423)	$	(378,751)
Total stockholders' equity	$	171,476	$	(4,423)	$	167,053
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	1,008,907	$	(5,824)	$	1,003,083


	Three Months Ended September 30, 2022
Condensed Consolidated Statement of Comprehensive Income (Loss) (in thousands)	As Previously Reported		Adjustment		As Revised
Cost of sales	$	27,217	$	212	$	27,429
Gross profit	$	61,575	$	(212)	$	61,363
Loss from operations	$	(4,141)	$	(212)	$	(4,353)
Loss before provision for income taxes	$	(690)	$	(212)	$	(902)
Net income (loss)	$	131	$	(212)	$	(81)
Comprehensive loss	$	(1,505)	$	(212)	$	(1,717)


	Nine Months Ended September 30, 2022
Condensed Consolidated Statement of Comprehensive Income (Loss) (in thousands, except per share amounts)	As Previously Reported		Adjustment		As Revised
Cost of sales	$	82,577	$	2,878	$	85,455
Gross profit	$	185,166	$	(2,878)	$	182,288
Loss from operations	$	(20,515)	$	(2,878)	$	(23,393)
Income before provision for income taxes	$	42,439	$	(2,878)	$	39,561
Net income	$	40,569	$	(2,878)	$	37,691
Comprehensive income	$	35,101	$	(2,878)	$	32,223
Net income per share - Basic	$	0.27	$	(0.02)	$	0.25
Net loss per share - Diluted	$	(0.20)	$	(0.02)	$	(0.22)


	Nine Months Ended September 30, 2022
Condensed Consolidated Statement of Cash Flows (in thousands)	As Previously Reported		Adjustment		As Revised
Net income	$	40,569	$	(2,878)	$	37,691
Changes in operating assets and liabilities:
Inventories	$	(75,007)	$	2,878	$	(72,129)

Income Taxes (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jul. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax [Line Items]
Income tax expense (benefit)		$ 3,479	$ (821)	$ (2,376)	$ 1,870
Effective tax rate (as a percent)		(4.90%)	91.00%	2.60%	4.70%
Gross unrecognized tax benefits		$ 400	$ 100	$ 400	$ 100
Employee retention credit	$ 5,400
Other Income
Income Tax [Line Items]
Employee retention credit	4,900
Interest Income
Income Tax [Line Items]
Employee retention credit	$ 500

Restructuring Charges (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
Restructuring Charges (Details) - USD ($) $ in Thousands	Oct. 31, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 12, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 600
Inventory write-down			$ 11,905	$ 5,667
Syndeo Program reserves		32,052	32,052			$ 0
Syndeo Program
Restructuring Cost and Reserve [Line Items]
Restructuring charges		44,306
Inventory write-down		18,800
Restructuring costs incurred		12,254
Syndeo Program reserves		$ 32,052	$ 32,052
Subsequent event
Restructuring Cost and Reserve [Line Items]
Warranty extension period	1 year
Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring expected costs					$ 9,000
Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring expected costs					$ 11,000

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The tax provisions for the three and nine months ended September 30, 2023 and 2022 were computed using the estimated effective tax rates projected for domestic and international taxable jurisdictions for the full year as adjusted for discrete items arising during each quarter. Income tax benefit for the nine months ended September 30, 2023 was $2.4 million. Income tax expense for the nine months ended September 30, 2022 was $1.9 million. Income tax expense for the three months ended September 30, 2023 was $3.5 million. Income tax benefit for the three months ended September 30, 2022 was $0.8 million. The effective tax rate for the three and nine months ended September 30, 2023 is (4.9)% and 2.6%. The effective tax rate for the three and nine months ended September 30, 2022 was 91.0% and 4.7%. The effective tax rate differs from the federal statutory rate due primarily to a full valuation allowance against the Company’s U.S. deferred tax assets, foreign jurisdictions that are taxed at different rates, state taxes, and the impact of discrete items that may occur in any given year but which are not consistent from year to year. The Company has established a valuation allowance in the U.S. and Singapore against a portion of its remaining deferred tax assets because it is more likely than not that certain deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considers numerous factors including historical profitability, the amount of future taxable income, and the existence of taxable temporary differences that can be used to realize deferred tax assets. Additionally, the Company applies ASC 740, the accounting standard addressing the accounting for uncertainty in income taxes that prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The Company has gross unrecognized tax benefits of $0.4 million and $0.1 million for the nine months ended September 30, 2023 and September 30, 2022, respectively. The Inflation Reduction Act, signed into law on August 16, 2022, provides tax incentives for certain industries and imposes a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on stock buybacks. The Company may be subject to the new excise tax on certain stock buybacks that occur after December 31, 2022. The Company does not anticipate a material impact from the Inflation Reduction Act on its condensed consolidated financial statements. During July 2023, the Company received $5.4 million for the Employee Retention Credit under the Coronavirus Aid, Relief, and Economic Security Act, of which $4.9 million was recorded in other (income) expense, net and $0.5 million was recorded in interest income on the Company’s condensed consolidated statements of comprehensive income (loss).

Revenue - Narrative (Details)	9 Months Ended
Revenue - Narrative (Details)	Sep. 30, 2023 segment
Revenue from Contract with Customer [Abstract]
Number of operating segments	1
Number of reportable segments	1

Stockholders’ Equity (Details)			3 Months Ended		9 Months Ended
Stockholders’ Equity (Details)	Nov. 09, 2022 USD ($) program shares	Sep. 27, 2022 USD ($) program shares	Sep. 30, 2023 USD ($) vote $ / shares shares	Jun. 30, 2023 USD ($)	Sep. 30, 2023 USD ($) vote $ / shares shares	Sep. 30, 2022 USD ($)	Sep. 12, 2023 USD ($)	Dec. 31, 2022 $ / shares shares	Sep. 26, 2022 USD ($)	May 04, 2021 $ / shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares)			320,000,000		320,000,000			320,000,000
Common stock, par value (in dollars per share) \| $ / shares			$ 0.0001		$ 0.0001			$ 0.0001		$ 0.0001
Common stock, number of votes \| vote			1		1
Common stock, shares issued (in shares)			132,569,193		132,569,193			132,214,695
Common stock, shares outstanding (in shares)			132,569,193		132,569,193			132,214,695
Shares redeemed \| $			$ 4,800,000
Number of stock repurchase programs \| program	2	2
Payments for repurchase of common stock \| $					$ 0	$ 80,000,000
Payment of accelerated share repurchases \| $					$ 2,240,000
Preferred stock, shares authorized (in shares)			1,000,000		1,000,000
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001		$ 0.0001
Preferred stock, shares issued (in shares)			0		0			0
Preferred stock, shares outstanding (in shares)			0		0			0
Accelerated Share Repurchase
Class of Stock [Line Items]
Stock repurchased (in shares)	9,500,000	9,300,000
Payments for repurchase of common stock \| $	$ 100,000,000	$ 100,000,000
Stock repurchased during period, payment as a percentage of closing stock price	80.00%
Payment of accelerated share repurchases \| $				$ 2,200,000
Class A common stock
Class of Stock [Line Items]
Common stock repurchase authorized \| $							$ 100,000,000		$ 200,000,000
Stock repurchased (in shares)			800,000
Repurchase and retirement of common stock (in shares)			400,000
Class A common stock \| Accelerated Share Repurchase
Class of Stock [Line Items]
Common stock repurchase authorized \| $	$ 200,000,000

Revision for Immaterial Misstatements - Condensed Consolidated Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Income (Loss)	$ (73,818)	$ 3,364	$ (20,259)	$ (81)	$ 6,317	$ 31,455	$ (90,713)	$ 37,691
Changes in operating assets and liabilities:
Inventories							$ 3,426	(72,129)
Previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Income (Loss)				131				40,569
Changes in operating assets and liabilities:
Inventories								(75,007)
Revision of Prior Period, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Income (Loss)				$ (212)				(2,878)	$ 200
Changes in operating assets and liabilities:
Inventories								$ 2,878

Description of Business	9 Months Ended
Description of Business	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business The Beauty Health Company (the “Company”) is a global category-creating company delivering skin health experiences that help consumers reinvent their relationship with their skin, bodies and self-confidence. The Company and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. The Company’s brands are pioneers: Hydrafacial in hydradermabrasion; SkinStylus in microneedling; and Keravive in scalp health. Together, with its powerful community of estheticians, partners and consumers, the Company is personalizing skin health for all ages, genders, skin tones, and skin types. Historical Information The Company (f.k.a. Vesper Healthcare Acquisition Corp.) was incorporated in the State of Delaware on July 8, 2020. On May 4, 2021, we consummated the previously announced business combination pursuant to that certain Agreement and Plan of Merger, dated December 8, 2020, by and among Vesper Healthcare Acquisition Corp. (“Vesper Healthcare”), Hydrate Merger Sub I, Inc. (“Merger Sub I”), Hydrate Merger Sub II, LLC (“Merger Sub II”), LCP Edge Intermediate, Inc., the indirect parent of HydraFacial LLC, f.k.a. Edge Systems LLC (“Hydrafacial”), and LCP Edge Holdco, LLC (“LCP,” or “Former Parent,” and, in its capacity as the stockholders’ representative, the “Stockholders’ Representative”) (the “Merger Agreement”), which provided for: (a) the merger of Merger Sub I with and into Hydrafacial, with Hydrafacial continuing as the surviving corporation (the “First Merger”), and (b) immediately following the First Merger and as part of the same overall transaction as the First Merger, the merger of Hydrafacial with and into Merger Sub II, with Merger Sub II continuing as the surviving entity (the “Second Merger” and, together with the First Merger, the “Mergers” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). As a result of the First Merger, the Company owns 100% of the outstanding common stock of Hydrafacial and each share of common stock and preferred stock of Hydrafacial was cancelled and converted into the right to receive a portion of the consideration payable in connection with the Mergers. As a result of the Second Merger, the Company owns 100% of the outstanding interests in Merger Sub II. In connection with the closing of the Business Combination, the Company owns, directly or indirectly, 100% of the stock of Hydrafacial and its subsidiaries and the stockholders of Hydrafacial as of immediately prior to the effective time of the First Merger (the “Hydrafacial Stockholders”) hold a portion of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”). Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. These statements reflect all normal and recurring adjustments which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows of the Company for the interim periods presented. These interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in, or presented as exhibits to, the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Subsequent to the issuance of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, during the six months ended June 30, 2023, the Company identified prior period misstatements related to the elimination of intercompany balances and right of return assets. Although the Company concluded that these misstatements were not material, either individually or in the aggregate, the Company elected to revise its previously issued consolidated financial statements to correct for these misstatements. These misstatements impacted the fiscal years 2020 to 2022 and the three months ended March 31, 2023. The revision of the previously issued consolidated financial statements is presented in the accompanying unaudited consolidated financial statements and related disclosures. For further detail, refer to Note 16 - Revision for Immaterial Misstatements. Certain prior period amounts have been reclassified to conform to the current period presentation, including previously reported inventories in the condensed consolidated statement of cash flows which was disclosed net of a $5.7 million inventory write-down. We reclassified the inventory write-down in the prior period to conform to the current period presentation of inventory write-down as an adjustment to reconcile net income to net cash from operating activities. This reclassification had no effect on the previously reported net cash used for operating activities.

Related-Party Transactions	9 Months Ended
Related-Party Transactions	Sep. 30, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions Registration Rights Agreement In connection with the consummation of the Business Combination, on May 4, 2021, the Company entered into that certain Amended and Restated Registration Rights Agreement (the “Registration Rights Agreement”) with BLS Investor Group LLC (the “Sponsor”) and the Hydrafacial stockholders. Pursuant to the terms of the Registration Rights Agreement, (i) any outstanding shares of Class A Common Stock or any other equity securities (including the Private Placement Warrants and including shares of Class A Common Stock issued or issuable upon the exercise of any other equity security) of the Company held by the Sponsor or the Hydrafacial stockholders (together, the “Restricted Stockholders”) as of the date of the Registration Rights Agreement or thereafter acquired by a Restricted Stockholder (including the shares of Class A Common Stock issued upon conversion of the 11,500,000 shares of Class B Common Stock (the “Founder Shares”) that were owned by the Sponsor and converted into shares of Class A Common Stock in connection with the Business Combination and upon exercise of any Private Placement Warrants) and shares of Class A Common Stock issued as earn-out shares to the Hydrafacial stockholders and (ii) any other equity security of the Company issued or issuable with respect to any such share of common stock by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise will be entitled to registration rights. The Registration Rights Agreement provides that the Company will, within 60 days after the consummation of the Business Combination, file with the Securities and Exchange Commission (the “SEC”) a shelf registration statement registering the resale of the shares of common stock held by the Restricted Stockholders and will use its reasonable best efforts to have such registration statement declared effective as soon as practicable after the filing thereof, but in no event later than 60 days following the filing deadline. The Company filed such registration statement on July 19, 2021 and it was declared effective by the SEC on July 26, 2021. The Hydrafacial stockholders are entitled to make up to an aggregate of two demands for registration, excluding short form demands, that the Company register shares of common stock held by these parties. In addition, the Restricted Stockholders have certain “piggy-back” registration rights. The Company will bear the expenses incurred in connection with the filing of any registration statements filed pursuant to the terms of the Registration Rights Agreement. The Company and the Restricted Stockholders agree in the Registration Rights Agreement to provide customary indemnification in connection with any offerings of common stock effected pursuant to the terms of the Registration Rights Agreement. Pursuant to the Registration Rights Agreement, the Sponsor agreed to restrictions on the transfer of securities issued to it in the Company’s initial public offering, which (i) in the case of the Founder Shares is one year after the completion of the Business Combination unless (A) the closing price of the common stock equals or exceeds $12.00 per share for 20 days out of any 30-trading-day period commencing at least 150 days following the closing of the Business Combination or (B) the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property, and (ii) in the case of the Private Placement Warrants and the respective Class A Common Stock underlying the Private Placement Warrants is 30 days after the completion of the Business Combination. The Sponsor and its permitted transferees will also be required, subject to the terms and conditions in the Registration Rights Agreement, not to transfer their Private Placement Warrants (as defined in the Registration Rights Agreement) or shares of common stock issuable upon the exercise thereof for 30 days following the closing. Investor Rights Agreement In connection with the consummation of the Business Combination, on May 4, 2021, the Company and LCP Edge Holdco, LLC (“LCP”) entered into that certain Investor Rights Agreement (the “Investor Rights Agreement”). Pursuant to the Investor Rights Agreement, LCP has the right to designate a number of directors for appointment or election to the Company’s board of directors as follows: (i) one director for so long as LCP holds at least 10% of the outstanding Class A Common Stock, (ii) two directors for so long as LCP holds at least 15% of the outstanding Class A Common Stock, and (iii) three directors for so long as LCP holds at least 40% of the outstanding Class A Common Stock. Pursuant to the Investor Rights Agreement, for so long as LCP holds at least 10% of the outstanding Class A Common Stock, LCP will be entitled to have at least one of its designees represented on the compensation committee and nominating and corporate governance committee of the Company’s board of directors.

Revision for Immaterial Misstatements - Condensed Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories	$ 74,878			$ 109,656
Prepaid expenses and other current assets	35,891			27,648
Total current assets	738,011			783,275
TOTAL ASSETS	973,074			1,003,083
Accounts payable	35,883			28,467
Income tax payable	1,990			1,429
Liabilities, Current	125,879			71,714
Liabilities	883,117			836,030
Accumulated deficit	(469,464)		$ 4,700	(378,751)
Total stockholders' equity	89,957	$ 161,842	152,408	167,053	$ 250,768	$ 345,406	$ 336,393	$ 298,034
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 973,074			1,003,083
Previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories				116,430
Prepaid expenses and other current assets				26,698
Total current assets				789,099
TOTAL ASSETS				1,008,907
Accounts payable				30,335
Income tax payable				962
Liabilities, Current				73,115
Liabilities				837,431
Accumulated deficit				(374,328)
Total stockholders' equity			$ 147,700	171,476		352,300		302,300
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY				1,008,907
Revision of Prior Period, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories				(6,774)
Prepaid expenses and other current assets				950
Total current assets				(5,824)
TOTAL ASSETS				(5,824)
Accounts payable				(1,868)
Income tax payable				467
Liabilities, Current				(1,401)
Liabilities				(1,401)
Accumulated deficit				(4,423)		$ (6,900)		$ (4,300)
Total stockholders' equity				(4,423)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY				$ (5,824)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Goodwill and Intangible Assets, net - Intangible assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Feb. 28, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 146,674		$ 114,806
Accumulated Amortization	(82,032)		(68,420)
Net Carrying Value	64,642		$ 46,386
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)			3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)			8 years
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	91,629		$ 73,188
Accumulated Amortization	(61,694)		(54,422)
Net Carrying Value	$ 29,935	$ 19,900	18,766
Developed technology \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	3 years
Developed technology \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	10 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 18,230		18,089
Accumulated Amortization	(10,147)		(7,602)
Net Carrying Value	$ 8,083		$ 10,487
Customer relationships \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years		5 years
Customer relationships \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	10 years		10 years
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 11,510		$ 10,907
Accumulated Amortization	(5,157)		(4,119)
Net Carrying Value	$ 6,353		$ 6,788
Estimated Useful Life (Years)	15 years		15 years
Capitalized software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 16,532		$ 9,620
Accumulated Amortization	(3,368)		(1,507)
Net Carrying Value	$ 13,164		$ 8,113
Capitalized software \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	3 years		3 years
Capitalized software \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years		5 years
Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,844		$ 776
Accumulated Amortization	(1,182)		(395)
Net Carrying Value	$ 4,662		$ 381
Estimated Useful Life (Years)	3 years		3 years
Patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 2,929		$ 2,226
Accumulated Amortization	(484)		(375)
Net Carrying Value	$ 2,445		$ 1,851
Patents \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	3 years		3 years
Patents \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	19 years		19 years

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Ageless On October 21, 2020, Hydrafacial filed a complaint (the “California Complaint”) against Ageless Serums LLC (“Ageless”) in the United States District Court for the Central District of California, Western Division, captioned Edge Systems LLC v. Ageless Serums LLC, Case No. 2:20-cv-09669-FMO-PVC (the “California Case”), for various claims, including contributory trademark infringement, false designation of origin, induced breach of contract, tortious interference with contractual relations, and unfair competition. In the California Complaint, Hydrafacial alleged that Ageless is selling its serums to Hydrafacial customers and intentionally encouraging those customers to market treatments performed by such customers as “Hydrafacial Treatments,” in violation of the customers’ license agreements with Hydrafacial and that Ageless is improperly marketing its products for use as part of the Hydrafacial treatment. Hydrafacial sought monetary damages and injunctive relief from Ageless in the California Case. Additionally, on December 22, 2020, Hydrafacial filed a complaint (the “Texas Complaint”) against Ageless in the United States District Court for the Southern District of Texas, Houston Division, captioned Edge Systems LLC v. Ageless Serums LLC, Case No. 4:20-cv 04335 (the “Texas Case”), alleging infringement of six of Hydrafacial’s patents. Hydrafacial is seeking monetary damages and injunctive relief from Ageless in the Texas Case. On November 30, 2020, Ageless answered the California Complaint and asserted counterclaims for violation of antitrust, California statutory and common law unfair competition, false advertising, defamation, and tortious interference with prospective and actual economic advantage. On July 12, 2021, Ageless answered the Texas Complaint and asserted similar counterclaims as those in the California Case. On May 5, 2022, Ageless filed a Chapter 11 bankruptcy petition in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (the “Houston Bankruptcy Court”), and the California Case and Texas Case were thus stayed under 11 U.S.C. Section 362(a)(1). On September 7, 2022, Hydrafacial filed a proof of claim, asserting general unsecured claim for damages arising from claims alleged in the California Case and Texas Case. On January 4, 2023, Hydrafacial filed an Objection to the Confirmation of Debtor’s Subchapter V Plan of Reorganization and Brief in Support. On March 8, 2023, Hydrafacial and Ageless engaged in mediation to settle the claims alleged in the California Case and Texas Case. Ultimately, Hydrafacial and Ageless reached a tentative settlement agreement of all claims alleged in the California Case and Texas Case. On September 18, 2023, Ageless filed the Debtor’s Third Amended Subchapter V Plan of Reorganization (the “Plan”). The Plan incorporated the material terms of the settlement that Hydrafacial and Ageless reached at the mediation. Under the Plan, Ageless is required to pay to Hydrafacial $0.1 million on or before October 15, 2023 and tender thirteen (13) subsequent quarterly payments, each consisting of $0.1 million, for a total of $1.4 million. Ageless also agreed to various sales and marketing conditions that restrict Ageless from selling to Hydrafacial’s customers. Ageless agreed to other covenants that are contained in Article VIII of the Plan. The Plan also includes mutual releases between Hydrafacial and Ageless. The Plan includes remedies for Hydrafacial’s benefit in the event that Ageless defaults on any of its material obligations under the Plan. The Houston Bankruptcy Court considered confirmation of the Plan at a hearing held on September 22, 2023, and Hydrafacial expressed its support of the Plan at the hearing. The Houston Bankruptcy Court entered the Findings of Fact, Conclusions of Law, and Order Confirming Debtor’s Third Amended Plan of Reorganization on September 22, 2023. The Plan contains various conditions precedent to the effectiveness of the Plan that are contained in Article X of the Plan. The Plan requires Hydrafacial to dismiss the California Case and the Texas Case within ten (10) days of the occurrence of the effective date of the Plan. On October 13, 2023, Ageless tendered its initial payment of $0.1 million to Hydrafacial pursuant to the terms and conditions of the Plan. Cartessa On December 14, 2020, Hydrafacial filed a complaint (the “Cartessa Complaint”) against Cartessa Aesthetics, LLC (“Cartessa”) in the United States District Court for the Eastern District of New York (the “New York Court”), captioned Edge Systems LLC v. Cartessa Aesthetics, LLC, Case No. 1:20-cv-6082, for patent infringement arising from Cartessa’s sale of Cartessa’s hydradermabrasion system that Hydrafacial alleged has infringed five of Hydrafacial’s patents on its device. Hydrafacial narrowed its allegation in the Cartessa Complaint to assert infringement of just four of its patents. On September 15, 2022, the New York Court granted Hydrafacial’s Motion for Summary Judgment of No Unclean Hands and denied Cartessa’s Motion for Summary Judgment of non-infringement on three of the four patents-in-suit. On June 6, 2023, the New York Court granted Hydrafacial’s Motion for Summary Judgment of No Invalidity of the fourth patent-in-suit and granted Cartessa’s Motion for Summary Judgment of non-infringement of that same patent. As of the date of this report, Hydrafacial and Cartessa are awaiting the New York Court to set a trial date on Hydrafacial’s remaining three patents-in-suit in the Cartessa Complaint. Hydrafacial is seeking monetary damages and plans to vigorously pursue its claims against Cartessa. Hydrafacial also plans to appeal the New York Court’s grant of Cartessa’s Motion for Summary Judgment.

Share-Based Payments - Narrative (Details) $ in Millions	9 Months Ended
Share-Based Payments - Narrative (Details) $ in Millions	Sep. 30, 2023 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 64.2
Unrecognized compensation expense, period for recognition	2 years
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum employee subscription rate	10.00%

Property and Equipment, net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation and amortization	$ (18,339)	$ (12,494)
Property and equipment, net	16,062	18,184
Depreciable property and equipment
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	33,890	29,303
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	$ 6,405	5,364
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)	2 years
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)	7 years
Computers and equipment
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	$ 5,452	4,901
Computers and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)	3 years
Computers and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)	5 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	$ 8,913	6,427
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)	2 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)	5 years
Autos and trucks
Property, Plant and Equipment [Line Items]
Useful life (years)	5 years
Plant and equipment, including finance lease, gross	$ 234	161
Tooling
Property, Plant and Equipment [Line Items]
Useful life (years)	5 years
Plant and equipment, including finance lease, gross	$ 715	638
Leasehold improvements
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	12,171	11,812
Construction in progress
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	$ 511	$ 1,375

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021		150,598,047
Beginning balance at Dec. 31, 2021	$ 298,034	$ 16	$ 722,250	$ (1,257)	$ (422,975)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	31,455				31,455
Issuance of common stock pursuant to equity compensation plan (in shares)		5,184
Share-based compensation	7,049		7,049
Foreign currency translation adjustments	(145)			(145)
Ending balance (in shares) at Mar. 31, 2022		150,603,231
Ending balance at Mar. 31, 2022	336,393	$ 16	729,299	(1,402)	(391,520)
Beginning balance (in shares) at Dec. 31, 2021		150,598,047
Beginning balance at Dec. 31, 2021	298,034	$ 16	722,250	(1,257)	(422,975)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	37,691
Foreign currency translation adjustments	(5,468)
Ending balance (in shares) at Sep. 30, 2022		143,201,041
Ending balance at Sep. 30, 2022	250,768	$ 15	642,762	(6,725)	(385,284)
Beginning balance (in shares) at Dec. 31, 2021		150,598,047
Beginning balance at Dec. 31, 2021	$ 298,034	$ 16	722,250	(1,257)	(422,975)
Ending balance (in shares) at Dec. 31, 2022	132,214,695	132,214,695
Ending balance at Dec. 31, 2022	$ 167,053	$ 14	550,320	(4,530)	(378,751)
Beginning balance (in shares) at Mar. 31, 2022		150,603,231
Beginning balance at Mar. 31, 2022	336,393	$ 16	729,299	(1,402)	(391,520)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	6,317				6,317
Issuance of common stock pursuant to equity compensation plan (in shares)		252,536
Shares withheld for tax withholdings on vested stock awards (in shares)		(29,475)
Shares withheld for tax withholdings on vested stock awards	(495)		(495)
Common Stock relating to acquisition (in shares)		28,733
Common Stock relating to asset acquisition	500		500
Share-based compensation	6,378		6,378
Foreign currency translation adjustments	(3,687)			(3,687)
Ending balance (in shares) at Jun. 30, 2022		150,855,025
Ending balance at Jun. 30, 2022	345,406	$ 16	735,682	(5,089)	(385,203)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(81)				(81)
Issuance of common stock pursuant to equity compensation plan (in shares)		64,775
Shares withheld for tax withholdings on vested stock awards (in shares)		(26,451)
Shares withheld for tax withholdings on vested stock awards	(370)		(370)
Repurchase and retirement of common stock (in shares)		(7,692,308)
Repurchase and retirement of Common Stock	(80,000)	$ (1)	(79,999)
Purchase of equity forward contract in connection with accelerated share repurchase	(20,000)		(20,000)
Share-based compensation	7,449		7,449
Foreign currency translation adjustments	(1,636)			(1,636)
Ending balance (in shares) at Sep. 30, 2022		143,201,041
Ending balance at Sep. 30, 2022	$ 250,768	$ 15	642,762	(6,725)	(385,284)
Beginning balance (in shares) at Dec. 31, 2022	132,214,695	132,214,695
Beginning balance at Dec. 31, 2022	$ 167,053	$ 14	550,320	(4,530)	(378,751)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(20,259)				(20,259)
Issuance of common stock pursuant to equity compensation plan (in shares)		473,049
Shares withheld for tax withholdings on vested stock awards (in shares)		(170,415)
Shares withheld for tax withholdings on vested stock awards	(2,195)		(2,195)
Issuance of Common Stock relating to employee stock purchase plan	2,034		2,034
Common Stock relating to acquisition (in shares)		109,625
Common Stock relating to asset acquisition	1,310		1,310
Share-based compensation	3,577		3,577
Foreign currency translation adjustments	888			888
Ending balance (in shares) at Mar. 31, 2023		132,626,954
Ending balance at Mar. 31, 2023	$ 152,408	$ 14	555,046	(3,642)	(399,010)
Beginning balance (in shares) at Dec. 31, 2022	132,214,695	132,214,695
Beginning balance at Dec. 31, 2022	$ 167,053	$ 14	550,320	(4,530)	(378,751)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(90,713)
Foreign currency translation adjustments	$ (572)
Ending balance (in shares) at Sep. 30, 2023	132,569,193	132,569,193
Ending balance at Sep. 30, 2023	$ 89,957	$ 14	564,509	(5,102)	(469,464)
Beginning balance (in shares) at Mar. 31, 2023		132,626,954
Beginning balance at Mar. 31, 2023	152,408	$ 14	555,046	(3,642)	(399,010)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	3,364				3,364
Issuance of common stock pursuant to equity compensation plan (in shares)		254,742
Shares withheld for tax withholdings on vested stock awards (in shares)		(83,234)
Shares withheld for tax withholdings on vested stock awards	(545)		(545)
Issuance of Common Stock relating to employee stock purchase plan (in shares)		82,955
Issuance of Common Stock relating to employee stock purchase plan	698		698
Accelerated share repurchase payment	(2,240)		(2,240)
Share-based compensation	8,524		8,524
Foreign currency translation adjustments	(367)			(367)
Ending balance (in shares) at Jun. 30, 2023		132,881,417
Ending balance at Jun. 30, 2023	161,842	$ 14	561,483	(4,009)	(395,646)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(73,818)				(73,818)
Issuance of common stock pursuant to equity compensation plan (in shares)		157,749
Shares withheld for tax withholdings on vested stock awards (in shares)		(50,731)
Shares withheld for tax withholdings on vested stock awards	(331)		(331)
Repurchase and retirement of common stock (in shares)		(419,242)
Repurchase and retirement of Common Stock	(4,828)		(4,828)
Share-based compensation	8,185		8,185
Foreign currency translation adjustments	$ (1,093)			(1,093)
Ending balance (in shares) at Sep. 30, 2023	132,569,193	132,569,193
Ending balance at Sep. 30, 2023	$ 89,957	$ 14	$ 564,509	$ (5,102)	$ (469,464)

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 559,444	$ 568,197
Accounts receivable, net of allowances for estimated credit losses of $4,752 and $2,929 at September 30, 2023 and December 31, 2022, respectively	66,809	76,494
Inventories	74,878	109,656
Income tax receivable	989	1,280
Prepaid expenses and other current assets	35,891	27,648
Total current assets	738,011	783,275
Property and equipment, net	16,062	18,184
Right-of-use assets, net	13,343	15,637
Intangible assets, net	64,642	46,386
Goodwill	124,679	124,593
Deferred income tax assets, net	798	815
Other assets	15,539	14,193
TOTAL ASSETS	973,074	1,003,083
Current liabilities:
Accounts payable	35,883	28,467
Accrued payroll-related expenses	20,752	21,677
Syndeo Program reserves	32,052	0
Lease liabilities, current	4,711	4,958
Income tax payable	1,990	1,429
Other accrued expenses	30,491	15,183
Total current liabilities	125,879	71,714
Lease liabilities, non-current	10,105	12,689
Deferred income tax liabilities, net	2,299	2,011
Warrant liabilities	7,109	15,473
Convertible senior notes, net	737,315	734,143
Other long-term liabilities	410	0
Total liabilities	883,117	836,030
Commitments (Note 10)
Stockholders’ equity
Class A Common Stock, $0.0001 par value; 320,000,000 shares authorized; 132,569,193 and 132,214,695 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	14	14
Additional paid-in capital	564,509	550,320
Accumulated other comprehensive loss	(5,102)	(4,530)
Accumulated deficit	(469,464)	(378,751)
Total stockholders’ equity	89,957	167,053
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 973,074	$ 1,003,083

Goodwill and Intangible Assets, net - Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 124,593
Foreign currency translation impact	86
Goodwill, ending balance	$ 124,679

Long-term Debt - Narrative (Details)	Sep. 14, 2021 USD ($)	Sep. 09, 2021 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Nov. 14, 2022 USD ($)
Call Option
Debt Instrument [Line Items]
Initial cap price (in dollars per share) \| $ / shares		$ 47.94
Premium over sales price		100.00%
Purchase of capped calls related to Convertible Senior Notes		$ 90,200,000
1.25% Convertible Senior Notes Due 2026 \| Convertible Debt
Debt Instrument [Line Items]
Long-term debt			$ 737,315,000	$ 734,143,000
Face amount	$ 750,000,000
Stated interest rate	1.25%		1.25%	1.25%
Accordion feature, settlement period	13 days
Accordion feature, increase limit	$ 100,000,000
1.25% Convertible Senior Notes Due 2026 \| Convertible Debt \| Level 2
Debt Instrument [Line Items]
Fair value of debt			$ 585,000,000	$ 567,000,000
Revolving Credit Facility \| Credit Agreement Due 2026 \| Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 50,000,000
Line of credit, accordion feature			50,000,000
Long-term debt			$ 0
Leverage ratio, maximum			3.00
Fixed charge coverage ratio, minimum			1.15

Balance Sheet Components - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Sales and VAT tax payables	$ 7,196	$ 4,904
Share repurchase	4,828	0
Accrued interest	4,688	2,344
Royalty liabilities	4,186	2,348
Note payable due seller	0	1,819
Other	9,593	3,768
Total other accrued expenses	$ 30,491	$ 15,183

Stockholders’ Equity	9 Months Ended
Stockholders’ Equity	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Stockholders’ Equity Common Stock The Company is authorized to issue 320,000,000 shares of Class A Common Stock, par value of $0.0001 per share. Holders of Class A Common Stock are entitled to one vote for each share. As of September 30, 2023 and December 31, 2022, there were 132,569,193 and 132,214,695, respectively, of Class A Common Stock issued and outstanding. The Company has not declared or paid any dividends with respect to its Class A Common Stock. Common Stock Repurchases On September 12, 2023, the Company’s board of directors approved a share repurchase program authorizing the Company to repurchase up to $100.0 million of the Company’s Class A Common Stock. Under the share repurchase program, repurchases can be made from time to time using a variety of methods, which may include open market purchases, privately negotiated transactions, transactions structured through investment banking institutions, or a combination of the foregoing. Under this share repurchase program, the Company repurchased approximately 0.8 million shares for $4.8 million during the three months ended September 30, 2023, of which 0.4 million shares were received and retired, and all of which were recorded in other accrued expenses as of September 30, 2023. On September 26, 2022, the Company’s board of directors approved a share repurchase program authorizing the Company to repurchase up to $200.0 million of the Company’s Class A Common Stock. The Company entered into two accelerated share repurchase agreements on September 27, 2022 and November 9, 2022, respectively, with a financial institution to repurchase a total of $200.0 million of Class A Common Stock. Under the September 27, 2022 accelerated share repurchase agreement, the Company repurchased approximately 9.3 million shares for $100.0 million. Under the November 9, 2022 accelerated share repurchase agreement, the Company made a payment of $100.0 million and received initial deliveries of approximately 9.5 million shares, which represented 80% of the payment amount divided by the Company’s closing stock price on that date. During the three months ended June 30, 2023, the Company paid $2.2 million as the final settlement of the November 9, 2022 accelerated share repurchase agreement, which was based upon the average daily volume weighted average price of the Company’s Class A Common Stock during the repurchase period, less an agreed upon discount. Preferred Stock The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2023 and December 31, 2022, there were no shares of preferred stock issued or outstanding.

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowances for doubtful accounts	$ 4,752	$ 2,929
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	320,000,000	320,000,000
Common stock, shares issued (in shares)	132,569,193	132,214,695
Common stock, shares outstanding (in shares)	132,569,193	132,214,695

Description of Business (Policies)	9 Months Ended
Description of Business (Policies)	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. These statements reflect all normal and recurring adjustments which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows of the Company for the interim periods presented. These interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in, or presented as exhibits to, the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Subsequent to the issuance of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, during the six months ended June 30, 2023, the Company identified prior period misstatements related to the elimination of intercompany balances and right of return assets. Although the Company concluded that these misstatements were not material, either individually or in the aggregate, the Company elected to revise its previously issued consolidated financial statements to correct for these misstatements. These misstatements impacted the fiscal years 2020 to 2022 and the three months ended March 31, 2023. The revision of the previously issued consolidated financial statements is presented in the accompanying unaudited consolidated financial statements and related disclosures. For further detail, refer to Note 16 - Revision for Immaterial Misstatements.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Recent accounting pronouncements pending adoption not discussed in this Form 10-Q are either not applicable to the Company or are not expected to have a material impact on the Company.

Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Liabilities
Warrant liabilities	$ 7,109	$ 15,473
Recurring \| Money market funds
Assets
Money market funds	495,300	513,009
Recurring \| Private Placement Warrants
Liabilities
Warrant liabilities	7,109	15,473
Level 1 \| Recurring \| Money market funds
Assets
Money market funds	495,300	513,009
Level 1 \| Recurring \| Private Placement Warrants
Liabilities
Warrant liabilities	0	0
Level 2 \| Recurring \| Money market funds
Assets
Money market funds	0	0
Level 2 \| Recurring \| Private Placement Warrants
Liabilities
Warrant liabilities	0	0
Level 3 \| Recurring \| Money market funds
Assets
Money market funds	0	0
Level 3 \| Recurring \| Private Placement Warrants
Liabilities
Warrant liabilities	$ 7,109	$ 15,473

New Accounting Pronouncements	9 Months Ended
New Accounting Pronouncements	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recent accounting pronouncements pending adoption not discussed in this Form 10-Q are either not applicable to the Company or are not expected to have a material impact on the Company.

Fair Value Measurements - Narrative (Details) - Private Placement Warrants - $ / shares	1 Months Ended
	Oct. 31, 2020	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued (in shares)	9,333,333
Warrants, exercise price (in dollars per share)	$ 11.50
Warrants outstanding (in shares)		7,000,000	7,000,000

Related-Party Transactions (Details) - Related Party	May 04, 2021 demand tradingDay $ / shares shares
Related Party Transaction [Line Items]
Stock issued upon conversion (in shares) \| shares	11,500,000
Registration Rights Agreement, filing timeline	60 days
Registration Rights Agreement, number of demands for registration allowed \| demand	2
Private Placement Warrants
Related Party Transaction [Line Items]
Reverse recapitalization, contingent consideration, earnout period	30 days
LCP
Related Party Transaction [Line Items]
Reverse recapitalization, threshold percentage to designate one director	10.00%
Reverse recapitalization, threshold percentage to designate two directors	15.00%
Reverse recapitalization, threshold percentage to designate three directors	40.00%
Reverse recapitalization, threshold percentage to designate one director on board	10.00%
Vesper Founders
Related Party Transaction [Line Items]
Reverse recapitalization, contingent consideration, earnout period	1 year
Reverse recapitalization, contingent consideration, stock price trigger (in dollars per share) \| $ / shares	$ 12.00
Reverse recapitalization, contingent consideration, threshold days	20
Reverse recapitalization, contingent consideration, consecutive threshold days	30
Reverse recapitalization, contingent consideration, commencement period	150 days

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-39565
Entity Registrant Name	The Beauty Health Company
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1908962
Entity Address, Address Line One	2165 Spring Street
Entity Address, City or Town	Long Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90806
City Area Code	800
Local Phone Number	603-4996
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	SKIN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		131,266,839
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001818093

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (73,818)	$ 3,364	$ (20,259)	$ (81)	$ 6,317	$ 31,455	$ (90,713)	$ 37,691

Balance Sheet Components - Schedule of accrued payroll-related expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Accrued sales commissions	$ 8,049	$ 10,523
Accrued compensation	6,973	4,154
Accrued benefits	4,011	5,643
Accrued payroll taxes	1,719	1,357
Total accrued payroll-related expenses	$ 20,752	$ 21,677